Issued Patents All Time
Showing 1–25 of 112 patents
| Patent # | Title | Co-Inventors | Date |
|---|---|---|---|
| 12364761 | Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity | David M. Goldenberg | 2025-07-22 |
| 12310958 | Antibody-drug conjugates and uses thereof | David M. Goldenberg | 2025-05-27 |
| 12251441 | Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity | David M. Goldenberg | 2025-03-18 |
| 11541047 | Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity | David M. Goldenberg | 2023-01-03 |
| 11192955 | Efficacy of anti-Trop-2-SN-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors | David M. Goldenberg | 2021-12-07 |
| RE48751 | Immunoconjugates with an intracellularly-cleavable linkage | Sung-Ju Moon, David M. Goldenberg | 2021-09-28 |
| 11116846 | Antibody-drug conjugates and uses thereof | David M. Goldenberg | 2021-09-14 |
| 11077201 | Immunoconjugates with an intracellularly-cleavable linkage | Sung-Ju Moon, David M. Goldenberg | 2021-08-03 |
| 11066468 | Immunoconjugates with an intracellularly-cleavable linkage | — | 2021-07-20 |
| 11052156 | Antibody-drug conjugates and uses thereof | David M. Goldenberg | 2021-07-06 |
| 11052081 | Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132) | David M. Goldenberg | 2021-07-06 |
| 11020489 | Immunoconjugates with an intracellularly-cleavable linkage | Sung-Ju Moon, David M. Goldenberg | 2021-06-01 |
| 10918721 | Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity | David M. Goldenberg | 2021-02-16 |
| 10849986 | Antibody-drug conjugates and uses thereof | David M. Goldenberg | 2020-12-01 |
| 10751420 | Antibody-SN-38 immunoconjugates with a CL2A linker | Jonathan B. Gale, Nicholas J. Holman, David M. Goldenberg | 2020-08-25 |
| 10744129 | Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2 | David M. Goldenberg | 2020-08-18 |
| 10709701 | Efficacy of anti-HLA-DR antibody drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers | Thomas M. Cardillo, David M. Goldenberg | 2020-07-14 |
| 10682347 | Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity | David M. Goldenberg | 2020-06-16 |
| 10653793 | Antibody-drug conjugates and uses thereof | David M. Goldenberg | 2020-05-19 |
| 10561738 | Immunoconjugates with an intracellularly-cleavable linkage | Sung-Ju Moon, David M. Goldenberg | 2020-02-18 |
| 10413539 | Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132) | David M. Goldenberg | 2019-09-17 |
| 10322193 | Immunoconjugates with an intracellularly-cleavable linkage | Sung-Ju Moon, David M. Goldenberg | 2019-06-18 |
| 10280220 | Immunoconjugates with an intracellularly-cleavable linkage | — | 2019-05-07 |
| 10266605 | Efficacy of anti-trop-2-SN-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors | David M. Goldenberg | 2019-04-23 |
| 10265414 | Immunoconjugates with an intracellularly-cleavable linkage | Sung-Ju Moon, David M. Goldenberg | 2019-04-23 |